Orell Füssli Thalia AG acquires a stake in Evrlearn AG
Orell Füssli Thalia AG acquired a stake as Lead Investor in the digital community platform Evrlearn AG.
Mainova acquires mobiheat majority
Frankfurt-based Mainova AG has acquired a majority stake in Bavarian energy service provider mobiheat GmbH, including its Austria and Swiss subsidiaries, from Energieversorgung Offenbach AG (EVO) and the mobiheat founders.
msg systems ag acquired Optravis LLC
msg systems ag, an international IT consulting and system integration company based in Munich, has acquired Optravis LLC, based in Basel.
Inositec AG acquired by Vifor Pharma
Vifor Pharma acquires Zurich-based Inositec AG. Inositec develops first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders.
RELIEF launches Level 1 ADR Program in the United States
RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company, has launched its Level 1 American Depositary Receipt ("ADR") program in the United States. As of 18 November 2021, ADRs may be traded over the counter.
CRK joins the MYTY Group
The full-service PR and communications agency cR Kommunikation AG with offices in Bern, Basel and Zurich has joined the MYTY Group, a leading agency network in the DACH region.
Nautilus acquires Swiss motion tech company VAY, in Zurich
Nautilus, Inc., an innovation leader in home fitness, has acquired Zurich based VAY AG, a leader in motion detection and analysis.
A fund advised by AFINUM Management AG buys GS Swiss PCB
A fund advised by AFINUM Management AG signed on 8 October 2021 a share purchase agreement with exceet Group AG, a company of the exceet Group, to buy exceet Group's portfolio company GS Swiss PCB AG.
EGO Movement and TVS Motor agree on a strategic partnership
The fast-growing Swiss e-mobility company EGO Movement (the GO AG) has agreed on a long-term strategic partnership with the leading Indian mobility group TVS Motor.
Novaremed acquires Metys Pharmaceuticals
Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals.